Mendus AB

Equities

IMMU

SE0022239950

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-02-10 pm EST			5-day change	1st Jan Change
4.910 ^SEK	-2.77%		-5.39%	-12.32%

Feb. 02	Stockholm Bullets - Stillfront Drops Sharply After Billion-Krona Goodwill Write-Down	FW
Jan. 30	Mendus Draws on Loan Facility from Fenja Capital	FW

Mendus AB to Present Multiple Abstracts At Ash 2024, Including Survival Update of Advance II Trial with Lead Program Vididencel in AML

Published on 11/05/2024 at 09:00 am EST

S&P Capital IQ

MENDUS AB

-2.77%

Mendus AB announced that it will present updated survival data from the ongoing ADVANCE II trial with vididencel in acute myeloid leukemia (AML) at the upcoming ASH 2024 conference. Mendus will present updated survival data from the ADVANCE II trial, a Phase 2 trial addressing AML patients with measurable residual disease, during the 66th annual meeting of the American Society for Hematology (ASH), held December 7-10, 2024 (ASH 2024). The data will be presented on, December 8, at 6.00 pm PST.

Mendus will publish a press release summarizing the data on, December 9 at 8.00 am CET. Additionally, Mendus will present abstracts based on preclinical data supporting the combination of vididencel with the current AML therapy backbone drugs azacitidine and venetoclax and exploring the use of vididencel in chronic myeloid leukemia at ASH 2024.

Latest news about Mendus AB

Feb. 02	Stockholm Bullets - Stillfront Drops Sharply After Billion-Krona Goodwill Write-Down	FW
Jan. 30	Mendus Draws on Loan Facility from Fenja Capital	FW
Dec. 19	Mendus CEO Purchases Shares Worth One Million Kronor	FW
Dec. 19	Mendus CEO bought SEK 1.0 mln of co shares	RE
Dec. 10	Mendus AB Presents Summary of Data Related to its Lead Product Vididencel at ASH Conference	CI
Dec. 01	Mendus establishes large-scale GMP production for vididencel	FW
Dec. 01	Mendus AB Announces Large-Scale Vididencel GMP Production Milestone in Manufacturing Alliance with NorthX Biologics	CI
Nov. 27	Mendus Reports Positive Long-Term Data for Vididencel in Ovarian Cancer	FW
Nov. 27	Mendus AB announces positive 2-year follow-up data from Alison trial	RE
Nov. 27	Mendus AB Announces Positive 2-Year Follow-Up Data from the Alison Phase 1 Trial	CI
Nov. 19	Stockholm Bullets - Viscaria falls after announcing terms of issue	FW
Nov. 19	Mendus raises SEK 52.5 million through directed share issue	RE
Nov. 19	Mendus Conducts Directed Share Issue of SEK 52.5 Million at a 9.7 Percent Discount	FW
Nov. 18	Mendus Plans Directed Share Issue of Approximately SEK 50 Million	FW
Nov. 13	Mendus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Mendus AB, Q3 2025 Earnings Call, Nov 13, 2025
Nov. 13	Mendus Reports Reduced Operating Loss in Third Quarter	FW
25-10-28	Mendus board member Helén Tuvesson increases her shareholding	FW
25-10-24	Mendus Chairman Sven Andreasson Increases His Shareholding	FW
25-10-24	Mendus Board Member Hans Preusting Increases His Shareholding	FW
25-10-06	Redeye Lowers Target Price for Mendus to 17 SEK per Share	FW
25-10-06	Redeye Lowers Fair Value Estimate for Mendus to 17 Kronor (Previously 27)	FW
25-10-02	Stockholm Bullets - Hansa Biopharma declines after a major targeted new share issue	FW
25-10-02	Mendus Updates Development Strategy for Vididencel, Reduces Workforce	FW
25-10-02	Mendus announces updated clinical strategy, operational focus	RE

Chart Mendus AB

Duration

Period

IMMU: Dynamic Chart

Company Profile

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâ€™s own immune system against cancer. The Companyâ€™s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 11 - Q4 2025 Earnings Release

More about the company